Goldberg, Ronald B.

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation

Lipoproteins and Cardiovascular HealthClinical practice guidelines implementation

Cited by 6,185

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthHematopoietic Stem Cell Transplantation

Cited by 2,691

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthClinical practice guidelines implementation

Cited by 1,751

Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels: Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial

Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 986

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

Orchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 948

Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study

Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., Bray, G. A., Schade, D. S., Temprosa, M. G., White, N. H., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism

Folate and B Vitamins ResearchPorphyrin Metabolism and Disorders

Cited by 536

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 262

Long‐term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study

The Diabetes Prevention Program Outcomes Study Research Group; prepared on behalf of the DPPOS Research Group, Orchard, T. J., Temprosa, M., Barrett‐Connor, E., Fowler, S. E., Goldberg, R. B., Mather, K. J., Marcovina, S. M., Montez, M., Ratner, R. E., et al. (2013) · Diabetic Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 214

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 209

Relationship of Lipoproteins to Cardiovascular Events

Guyton, J. R., Slee, A. E., Anderson, T., Fleg, J. L., Goldberg, R. B., Kashyap, M. L., Marcovina, S. M., Nash, S. D., O'Brien, K. D., Weintraub, W. S., et al. (2013) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 182

Circuit resistance training improves the atherogenic lipid profiles of persons with chronic paraplegia

Nash, M. S., Jacobs, P. L., Mendez, A. J., & Goldberg, R. B. (2001) · The Journal of Spinal Cord Medicine

Spinal Cord Injury ResearchCardiovascular and exercise physiology

Cited by 147

Statin use and risk of developing diabetes: results from the Diabetes Prevention Program

Crandall, J. P., Mather, K., Rajpathak, S. N., Goldberg, R. B., Watson, K., Foo, S., Ratner, R., Barrett-Connor, E., & Temprosa, M. (2017) · BMJ Open Diabetes Research & Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 137

Regression From Prediabetes to Normal Glucose Regulation Is Associated With Reduction in Cardiovascular Risk: Results From the Diabetes Prevention Program Outcomes Study

Perreault, L., Temprosa, M., Mather, K. J., Horton, E., Kitabchi, A., Larkin, M., Montez, M. G., Thayer, D., Orchard, T. J., Hamman, R. F., et al. (2014) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 131

Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

Diabetes Prevention Program Research Group, Nathan, D. M., Knowler, W. C., Edelstein, S., Crandall, J. P., Dabelea, D., Goldberg, R. B., Kahn, S. E., Mather, K. J., Trandafirescu, G., et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 128

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 94

Does diabetes prevention translate into reduced long-term vascular complications of diabetes?

and the DPP Research Group, Nathan, D. M., Bennett, P. H., Crandall, J. P., Edelstein, S. L., Goldberg, R. B., Kahn, S. E., Knowler, W. C., Mather, K. J., Mudaliar, S., et al. (2019) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 91

The 'forgotten' bile acid sequestrants: is now a good time to remember?

Bays, H. E., & Goldberg, R. B. (2007) · American Journal of Therapeutics

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 83

The impact of physical activity on the prevention of type 2 diabetes: Evidence and lessons learned from the Diabetes Prevention Program, a long-standing clinical trial incorporating subjective and objective activity measures

Kriska, A. M., Rockette-Wagner, B., Edelstein, S. L., Bray, G. A., Delahanty, L. M., Hoskin, M. A., Horton, E. S., Venditti, E. M., Knowler, W. C., DPP Research Group, et al. (2021) · Diabetes Care

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

Factors affecting the decline in incidence of diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS)

Diabetes Prevention Program (DPP) Research Group, Hamman, R. F., Horton, E., Barrett-Connor, E., Bray, G. A., Christophi, C. A., Crandall, J., Florez, J. C., Fowler, S., Goldberg, R., et al. (2015) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 46

The Diabetes Prevention Program and Its Outcomes Study: NIDDK’s Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact

Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 29

Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program

Goldberg, R. B., Temprosa, M., Mele, L., Orchard, T., Mather, K., Bray, G., Horton, E., Kitabchi, A., Krakoff, J., Marcovina, S., et al. (2016) · Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 22

Increased genetic risk for β-cell failure is associated with β-cell function decline in people with prediabetes

Billings, L. K., Jablonski, K. A., Pan, Q., Florez, J. C., Franks, P. W., Goldberg, R. B., Hivert, M.-F., Kahn, S. E., Knowler, W. C., Lee, C. G., et al. (2024) · Diabetes

Genetic Associations and EpidemiologyDiabetes and associated disorders

Cited by 11